Accuracy of Autophagy-Related Genes for the Prognosis of Patients With Bladder Cancer

By Patrick Daly - Last Updated: February 11, 2022

According to a recent study, the prognosis of patients with bladder cancer (BC) can be improved via earlier diagnosis; however, the study posited that current commonly used predictors, such as patients’ general condition, histological grade, and pathological stage, are not accurate enough to indicate patients that may require invasive surgery for an improved prognosis. Co-lead authors Shiyuan Peng, Shanjin Ma, and Fa Yang and colleagues uncovered autophagy-related genes (ARGs) that appeared to be associated with BC prognosis and constructed a model based on those prognosis-related differentially expressed ARGs (PDEARGs).

The study, published in Scientific Reports, utilized data on individuals with BC from The Cancer Genome Atlas (TCGA) project database as well as ARG lists from the Human Autophagy Database. The Wilcox test method was used to identify the PDEARGs and multivariate Cox regression analysis was used to construct the prognostic model. Then, the model’s predictive accuracy, independent forecasting capacity, and correlation between the model and clinical variables or tumor microenvironment were evaluated with R software and enrichment analysis.

According to the report, the team observed that the risk scoring produced by their PDEARGs-based model effectively reflected patients’ deteriorated clinical features and tumor-promoting microenvironments. Furthermore, the authors noted that several immune-related gene ontology terms were significantly enriched by PDEARGS, which they suggested could “provide insights for present model and propose potential therapeutic targets for [BC] patients.”

Ultimately, the authors presented their model as a feasible and effective tool for health care professionals to make a more optimal decision regarding a patient’s treatment plan. They closed their report with the position that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with BC.